The latest news on next-generation sequencing.
The hospital is in the process of clinically validating a sequencing pipeline for its pediatric cancer patients, with the goal of demonstrating clinical utility.
CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.
The firms plan to use Natera's cell-free DNA liquid biopsy assay to monitor patients' response to Amal's cancer vaccine in combination with immunotherapy.
The study adds to growing evidence around the utility of cell-free DNA testing in lung cancer patients, while highlighting shortcomings of the approach.
The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.
Experts discussed the benefits and challenges of implementing precision medicine protocols for oncology patients at this week's Tri-Conference meeting
The company will launch a clinical version of its liquid biopsy assay in the second quarter and plans to launch clinical trials that make the case for reimbursement.
The company ran 668,600 tests during the year, a 30 percent increase from its 2017 testing volume.